<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Peptide Protocol Blog</title>
    <link>https://peptide-calc.app/blog/</link>
    <atom:link href="https://peptide-calc.app/blog/feed.xml" rel="self" type="application/rss+xml" />
    <description>Practical posts on running a peptide protocol: GLP-1 titration, cold chain, COA reading, mixing rules, travel and injection technique.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 22 Jun 2026 12:00:00 GMT</lastBuildDate>
    <item>
      <title>GLP-1 + oral contraceptives interaction</title>
      <link>https://peptide-calc.app/blog/glp1-oral-contraceptives-interaction-real-or-overblown/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/glp1-oral-contraceptives-interaction-real-or-overblown/</guid>
      <pubDate>Mon, 22 Jun 2026 12:00:00 GMT</pubDate>
      <description>Tirzepatide labels include a warning about reduced oral contraceptive effectiveness. Semaglutide doesn't. The mechanism, the risk, and the backup-contraception period.</description>
    </item>
    <item>
      <title>Tirzepatide OSA approval — US yes, EU not yet</title>
      <link>https://peptide-calc.app/blog/tirzepatide-osa-approval-us-not-eu/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/tirzepatide-osa-approval-us-not-eu/</guid>
      <pubDate>Mon, 22 Jun 2026 12:00:00 GMT</pubDate>
      <description>FDA approved tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in 2024; EU approval is pending. The trial data, the indication, and what it means.</description>
    </item>
    <item>
      <title>Verifying online peptide pharmacy licensing</title>
      <link>https://peptide-calc.app/blog/licensing-pharmacy-verification-peptide-online/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/licensing-pharmacy-verification-peptide-online/</guid>
      <pubDate>Sun, 21 Jun 2026 12:00:00 GMT</pubDate>
      <description>Before buying compounded or prescription peptides online, verify the pharmacy is properly licensed in your state, accredited (e.g., LegitScript, NABP), and operating within 503A or 503B law.</description>
    </item>
    <item>
      <title>Appetite scoring — catching GLP-1 tolerance</title>
      <link>https://peptide-calc.app/blog/appetite-scoring-glp1-tolerance-rebound/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/appetite-scoring-glp1-tolerance-rebound/</guid>
      <pubDate>Sun, 21 Jun 2026 12:00:00 GMT</pubDate>
      <description>A simple 1–5 appetite rating per meal catches the earliest signs of GLP-1 tolerance or unexpected appetite return — weeks before the scale shows a plateau.</description>
    </item>
    <item>
      <title>Within-region vs across-region rotation</title>
      <link>https://peptide-calc.app/blog/within-region-vs-across-region-injection-rotation/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/within-region-vs-across-region-injection-rotation/</guid>
      <pubDate>Sat, 20 Jun 2026 12:00:00 GMT</pubDate>
      <description>Insulin guidelines recommend within-region rotation; weekly GLP-1 doesn't require it. The two strategies, their use cases, and how to choose.</description>
    </item>
    <item>
      <title>Weekly weight + 4-week moving average on GLP-1</title>
      <link>https://peptide-calc.app/blog/weekly-weight-tracking-four-week-moving-average-glp1/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/weekly-weight-tracking-four-week-moving-average-glp1/</guid>
      <pubDate>Sat, 20 Jun 2026 12:00:00 GMT</pubDate>
      <description>Daily weight on GLP-1 swings 2–4 lb from fluid alone. Weekly fasted weight with a 4-week moving average is the signal you can act on.</description>
    </item>
    <item>
      <title>Body-fat scales and GLP-1 drift</title>
      <link>https://peptide-calc.app/blog/bioimpedance-body-fat-scales-glp1-drift/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/bioimpedance-body-fat-scales-glp1-drift/</guid>
      <pubDate>Fri, 19 Jun 2026 12:00:00 GMT</pubDate>
      <description>Bioimpedance home scales measure resistance through tissue, not actual fat. Hydration changes on GLP-1 can move the body-fat reading 3–5% day to day independent of actual fat.</description>
    </item>
    <item>
      <title>BPC-157 dosing windows and plasma half-life</title>
      <link>https://peptide-calc.app/blog/bpc-157-dosing-windows-half-life-plasma/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/bpc-157-dosing-windows-half-life-plasma/</guid>
      <pubDate>Fri, 19 Jun 2026 12:00:00 GMT</pubDate>
      <description>BPC-157's plasma half-life is very short (~30 minutes), but the tissue effect may persist longer. What this means for dosing frequency: once-daily vs split-daily vs longer windows.</description>
    </item>
    <item>
      <title>What to log in a peptide-tracking app</title>
      <link>https://peptide-calc.app/blog/what-to-log-in-a-peptide-tracking-app/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/what-to-log-in-a-peptide-tracking-app/</guid>
      <pubDate>Thu, 18 Jun 2026 12:00:00 GMT</pubDate>
      <description>Dose, time, site, symptoms, weight, glucose — the seven categories that matter most for GLP-1 and other peptide protocols. What's essential and what isn't.</description>
    </item>
    <item>
      <title>mcg vs mg — the writing convention</title>
      <link>https://peptide-calc.app/blog/mcg-vs-mg-peptide-dose-writing-convention/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/mcg-vs-mg-peptide-dose-writing-convention/</guid>
      <pubDate>Thu, 18 Jun 2026 12:00:00 GMT</pubDate>
      <description>Writing peptide doses as &quot;mcg&quot; instead of &quot;µg&quot; prevents the 1,000× misread that happens when µg is mistaken for mg. The pharmacy convention and why it matters.</description>
    </item>
    <item>
      <title>Skytrofa — 6-month room-temperature cartridges</title>
      <link>https://peptide-calc.app/blog/skytrofa-six-month-room-temperature-cartridges/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/skytrofa-six-month-room-temperature-cartridges/</guid>
      <pubDate>Wed, 17 Jun 2026 12:00:00 GMT</pubDate>
      <description>Skytrofa (lonapegsomatropin) is a long-acting growth hormone with cartridges stable at room temperature for 6 months. The PEG conjugation chemistry and what changes for users.</description>
    </item>
    <item>
      <title>Spotting counterfeit Ozempic pens</title>
      <link>https://peptide-calc.app/blog/spotting-counterfeit-ozempic-pens/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/spotting-counterfeit-ozempic-pens/</guid>
      <pubDate>Wed, 17 Jun 2026 12:00:00 GMT</pubDate>
      <description>Counterfeit Ozempic pens have hospitalized users with unknown contents. Ten visible features to check on every pen — packaging, labeling, dial mechanism, batch tracking.</description>
    </item>
    <item>
      <title>Gallbladder disease on GLP-1 — meta-analysis</title>
      <link>https://peptide-calc.app/blog/glp1-gallbladder-disease-76-trial-meta-analysis/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/glp1-gallbladder-disease-76-trial-meta-analysis/</guid>
      <pubDate>Tue, 16 Jun 2026 12:00:00 GMT</pubDate>
      <description>A 76-trial meta-analysis showed GLP-1 use increases gallbladder disease risk by ~50%. Higher doses, longer duration, faster weight loss all compound. What to monitor.</description>
    </item>
    <item>
      <title>Bruising after peptide injection — normal vs hematoma</title>
      <link>https://peptide-calc.app/blog/bruising-after-peptide-injection-normal-vs-hematoma/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/bruising-after-peptide-injection-normal-vs-hematoma/</guid>
      <pubDate>Tue, 16 Jun 2026 12:00:00 GMT</pubDate>
      <description>A small bruise after subq peptide injection is normal. Large, repeated, or painful bruises mean something is off in technique or anatomy. How to tell which is which.</description>
    </item>
    <item>
      <title>Survodutide and mazdutide — GLP-1/glucagon duals</title>
      <link>https://peptide-calc.app/blog/survodutide-mazdutide-glp1-glucagon-dual-agonist/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/survodutide-mazdutide-glp1-glucagon-dual-agonist/</guid>
      <pubDate>Mon, 15 Jun 2026 12:00:00 GMT</pubDate>
      <description>Survodutide (Boehringer) and mazdutide (Innovent) are GLP-1/glucagon dual agonists in Phase 3. The glucagon arm reduces liver fat directly. Where they fit in the pipeline.</description>
    </item>
    <item>
      <title>Why most peptide therapies stay injectable</title>
      <link>https://peptide-calc.app/blog/why-most-peptide-therapies-stay-injectable/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/why-most-peptide-therapies-stay-injectable/</guid>
      <pubDate>Mon, 15 Jun 2026 12:00:00 GMT</pubDate>
      <description>Most peptide drugs are injectable because oral bioavailability is brutally bad. The three barriers (acid, proteases, epithelial size) and the few workarounds — SNAC, small molecules, sublingual.</description>
    </item>
    <item>
      <title>Hypoglycemia on GLP-1 + insulin or sulfonylurea</title>
      <link>https://peptide-calc.app/blog/glp1-hypoglycemia-insulin-sulfonylurea-risk/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/glp1-hypoglycemia-insulin-sulfonylurea-risk/</guid>
      <pubDate>Sun, 14 Jun 2026 12:00:00 GMT</pubDate>
      <description>GLP-1s alone rarely cause hypoglycemia, but combined with insulin or sulfonylureas (glipizide, glyburide) the risk is real and clinically significant. How to monitor.</description>
    </item>
    <item>
      <title>Reconstitution math — diluent volume and concentration</title>
      <link>https://peptide-calc.app/blog/peptide-reconstitution-math-diluent-volume-concentration/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/peptide-reconstitution-math-diluent-volume-concentration/</guid>
      <pubDate>Sun, 14 Jun 2026 12:00:00 GMT</pubDate>
      <description>The amount of diluent you add to a lyophilized peptide vial directly controls the per-dose volume. The math, the practical concentrations, and the syringe-precision tradeoff.</description>
    </item>
    <item>
      <title>EU vs US peptide storage labels</title>
      <link>https://peptide-calc.app/blog/eu-vs-us-peptide-storage-label-temperatures/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/eu-vs-us-peptide-storage-label-temperatures/</guid>
      <pubDate>Sat, 13 Jun 2026 12:00:00 GMT</pubDate>
      <description>EU labels use 22–25 °C for room-temperature peptide storage; US labels use 59–86 °F. The same molecule, different temperature ranges. Travel implications.</description>
    </item>
    <item>
      <title>BPC-157 oral vs injectable bioavailability</title>
      <link>https://peptide-calc.app/blog/bpc-157-oral-vs-injectable-bioavailability/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/bpc-157-oral-vs-injectable-bioavailability/</guid>
      <pubDate>Sat, 13 Jun 2026 12:00:00 GMT</pubDate>
      <description>Oral BPC-157 has roughly 5–10% the systemic bioavailability of injectable. Local GI effects are achievable orally; systemic effects mostly require injection. The data and the implications.</description>
    </item>
    <item>
      <title>Tell anesthesia about your GLP-1 before surgery</title>
      <link>https://peptide-calc.app/blog/tell-anesthesia-team-about-glp1-before-surgery/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/tell-anesthesia-team-about-glp1-before-surgery/</guid>
      <pubDate>Fri, 12 Jun 2026 12:00:00 GMT</pubDate>
      <description>GLP-1s slow gastric emptying for days after the last dose. Anesthesia teams now ask about GLP-1 use; risk of aspiration during induction is real. The disclosure protocol.</description>
    </item>
    <item>
      <title>Upper-arm GLP-1 — why you usually need a helper</title>
      <link>https://peptide-calc.app/blog/upper-arm-glp1-injection-needs-a-helper/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/upper-arm-glp1-injection-needs-a-helper/</guid>
      <pubDate>Fri, 12 Jun 2026 12:00:00 GMT</pubDate>
      <description>The posterior upper arm is a labeled GLP-1 injection site, but self-injecting there is awkward and risk-prone. When to use the arm, technique, and the helper case.</description>
    </item>
    <item>
      <title>Liraglutide vs semaglutide — daily vs weekly</title>
      <link>https://peptide-calc.app/blog/liraglutide-vs-semaglutide-daily-weekly-tradeoff/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/liraglutide-vs-semaglutide-daily-weekly-tradeoff/</guid>
      <pubDate>Thu, 11 Jun 2026 12:00:00 GMT</pubDate>
      <description>Liraglutide (Saxenda, Victoza) is daily; semaglutide (Ozempic, Wegovy) is weekly. The half-life math, the efficacy gap, and when daily dosing is the better choice.</description>
    </item>
    <item>
      <title>Semaglutide acetate vs free acid — salt form differences</title>
      <link>https://peptide-calc.app/blog/semaglutide-acetate-vs-free-acid-salt-form-difference/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/semaglutide-acetate-vs-free-acid-salt-form-difference/</guid>
      <pubDate>Thu, 11 Jun 2026 12:00:00 GMT</pubDate>
      <description>Compounded semaglutide can be the acetate salt or the free acid. They have different solubility, stability, and bioavailability. Why this matters for compounded supply.</description>
    </item>
    <item>
      <title>GLP-1 diarrhea — normal vs dehydrating</title>
      <link>https://peptide-calc.app/blog/glp1-diarrhea-normal-vs-dehydrating/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/glp1-diarrhea-normal-vs-dehydrating/</guid>
      <pubDate>Wed, 10 Jun 2026 12:00:00 GMT</pubDate>
      <description>GLP-1 diarrhea ranges from mild looseness in week 1 to clinically dehydrating in some users. How to tell which is which, and the red flags that mean stop and rehydrate.</description>
    </item>
    <item>
      <title>IU vs mg — insulin and growth hormone conversion</title>
      <link>https://peptide-calc.app/blog/iu-vs-mg-insulin-growth-hormone-conversion/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/iu-vs-mg-insulin-growth-hormone-conversion/</guid>
      <pubDate>Wed, 10 Jun 2026 12:00:00 GMT</pubDate>
      <description>International Units (IU) are activity, not mass. 1 IU insulin = 0.0347 mg; 1 IU human growth hormone = 0.333 mg. Why the conversion is per-drug, and the dosing traps.</description>
    </item>
    <item>
      <title>Reconstituted peptide shelf life</title>
      <link>https://peptide-calc.app/blog/reconstituted-peptide-shelf-life-bac-water-vs-saline/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/reconstituted-peptide-shelf-life-bac-water-vs-saline/</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 GMT</pubDate>
      <description>BAC water gives reconstituted peptides 28 days; sterile saline gives 24 hours. The chemistry behind each, and the times that matter for compounded GLP-1s.</description>
    </item>
    <item>
      <title>Orforglipron — small-molecule oral GLP-1</title>
      <link>https://peptide-calc.app/blog/orforglipron-small-molecule-glp1-not-a-peptide/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/orforglipron-small-molecule-glp1-not-a-peptide/</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 GMT</pubDate>
      <description>Orforglipron is a small-molecule GLP-1 agonist — no peptide chain, no SNAC, no empty-stomach rule. The mechanism, Phase 3 data, and what it changes for oral GLP-1.</description>
    </item>
    <item>
      <title>Reflux and GERD on GLP-1 — delayed gastric emptying</title>
      <link>https://peptide-calc.app/blog/glp1-reflux-gerd-delayed-gastric-emptying/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/glp1-reflux-gerd-delayed-gastric-emptying/</guid>
      <pubDate>Mon, 08 Jun 2026 12:00:00 GMT</pubDate>
      <description>Reflux on semaglutide or tirzepatide isn't a new problem — it's slow gastric emptying meeting a normal LES. The mechanism, the meal-pattern fix, and when to talk to the prescriber.</description>
    </item>
    <item>
      <title>Needle reuse causes lipodystrophy on weekly injections</title>
      <link>https://peptide-calc.app/blog/needle-reuse-lipodystrophy-weekly-injections/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/needle-reuse-lipodystrophy-weekly-injections/</guid>
      <pubDate>Mon, 08 Jun 2026 12:00:00 GMT</pubDate>
      <description>Reusing a pen needle compounds trauma per injection: blunted tip, microscopic burrs, increased tissue damage. The lipodystrophy data even with one injection per week.</description>
    </item>
    <item>
      <title>CagriSema REDEFINE — amylin plus semaglutide</title>
      <link>https://peptide-calc.app/blog/cagrisema-redefine-amylin-semaglutide-trial-results/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/cagrisema-redefine-amylin-semaglutide-trial-results/</guid>
      <pubDate>Sun, 07 Jun 2026 12:00:00 GMT</pubDate>
      <description>CagriSema combines cagrilintide (amylin analog) with semaglutide. The REDEFINE Phase 3 trial showed ~20.4% weight loss vs ~16% on semaglutide alone. What amylin adds.</description>
    </item>
    <item>
      <title>TB-500 vs Thymosin Beta-4 — the naming explained</title>
      <link>https://peptide-calc.app/blog/tb-500-vs-thymosin-beta-4-naming-explained/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/tb-500-vs-thymosin-beta-4-naming-explained/</guid>
      <pubDate>Sun, 07 Jun 2026 12:00:00 GMT</pubDate>
      <description>TB-500 is sold as &quot;synthetic Thymosin Beta-4,&quot; but most commercial TB-500 is a 7-residue active fragment, not the full 43-residue protein. Why it matters.</description>
    </item>
    <item>
      <title>GLP-1 constipation — the second-phase shift</title>
      <link>https://peptide-calc.app/blog/glp1-constipation-second-phase-shift/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/glp1-constipation-second-phase-shift/</guid>
      <pubDate>Sat, 06 Jun 2026 12:00:00 GMT</pubDate>
      <description>GLP-1 GI side effects shift. Weeks 1–4 are nausea-dominated; months 2–6 turn into constipation. Why the change, and the practical management.</description>
    </item>
    <item>
      <title>Reading peptide vial labels — the format trap</title>
      <link>https://peptide-calc.app/blog/peptide-vial-concentration-label-reading-errors/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/peptide-vial-concentration-label-reading-errors/</guid>
      <pubDate>Sat, 06 Jun 2026 12:00:00 GMT</pubDate>
      <description>A vial labeled &quot;5 mg/0.5 mL&quot; delivers exactly that concentration: 10 mg/mL. Common label formats and the assumption errors that cause overdose.</description>
    </item>
    <item>
      <title>Peptide degradation above 86 °F — hour by hour</title>
      <link>https://peptide-calc.app/blog/peptide-heat-degradation-above-86-fahrenheit/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/peptide-heat-degradation-above-86-fahrenheit/</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 GMT</pubDate>
      <description>A peptide pen left in a 100 °F car loses measurable activity within hours. The degradation curve at 30 °C, 35 °C, 40 °C, and what counts as a salvageable excursion.</description>
    </item>
    <item>
      <title>Why &quot;research use only&quot; is not a legal disclaimer</title>
      <link>https://peptide-calc.app/blog/research-use-only-peptide-label-not-legal-disclaimer/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/research-use-only-peptide-label-not-legal-disclaimer/</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 GMT</pubDate>
      <description>The &quot;research use only&quot; label on grey-market peptide vials is not a legal disclaimer. What it actually means, what it protects, and the legal exposure it does not erase.</description>
    </item>
    <item>
      <title>Fat vs muscle loss on GLP-1 — STEP substudies</title>
      <link>https://peptide-calc.app/blog/glp1-fat-vs-muscle-loss-step-body-comp-substudies/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/glp1-fat-vs-muscle-loss-step-body-comp-substudies/</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 GMT</pubDate>
      <description>STEP-1 and STEP-3 body-composition substudies measured fat vs lean mass loss with DXA. ~60–70% of total weight loss was fat; ~25–30% was lean tissue. The numbers, in context.</description>
    </item>
    <item>
      <title>Why insulin care about sites and GLP-1 barely does</title>
      <link>https://peptide-calc.app/blog/injection-site-absorption-insulin-vs-semaglutide/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/injection-site-absorption-insulin-vs-semaglutide/</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 GMT</pubDate>
      <description>Insulin absorption varies 20–40% between abdomen, thigh, and arm. Weekly GLP-1 absorption barely changes. The pharmacokinetic reason and what it means for rotation.</description>
    </item>
    <item>
      <title>SURPASS-2 — tirzepatide vs semaglutide head-to-head</title>
      <link>https://peptide-calc.app/blog/surpass-2-head-to-head-hba1c-tirzepatide-semaglutide/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/surpass-2-head-to-head-hba1c-tirzepatide-semaglutide/</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 GMT</pubDate>
      <description>SURPASS-2 put tirzepatide against semaglutide directly in type-2 diabetes. HbA1c −2.30% vs −1.86%; weight loss −12.4 kg vs −6.2 kg. What the trial actually measured.</description>
    </item>
    <item>
      <title>SNAC — the oral semaglutide absorption enhancer</title>
      <link>https://peptide-calc.app/blog/snac-absorption-enhancer-oral-semaglutide/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/snac-absorption-enhancer-oral-semaglutide/</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 GMT</pubDate>
      <description>SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) is the small molecule that gets oral semaglutide across the stomach wall. The biology, the limits, and the 30-minute window.</description>
    </item>
    <item>
      <title>Resistance training during GLP-1</title>
      <link>https://peptide-calc.app/blog/resistance-training-glp1-muscle-loss-prevention/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/resistance-training-glp1-muscle-loss-prevention/</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 GMT</pubDate>
      <description>Without resistance training, ~25–35% of weight lost on GLP-1 is muscle. With 2–3× weekly compound lifting, that drops to under 10%. The minimum-effective protocol.</description>
    </item>
    <item>
      <title>U-500 insulin and special syringes</title>
      <link>https://peptide-calc.app/blog/u500-insulin-special-syringes-fda-mandate/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/u500-insulin-special-syringes-fda-mandate/</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 GMT</pubDate>
      <description>U-500 insulin is 5× more concentrated than U-100. The FDA mandates U-500-specific syringes after fatal dosing errors. Why the rule exists and how to apply it.</description>
    </item>
    <item>
      <title>Freezing peptides is irreversible</title>
      <link>https://peptide-calc.app/blog/freezing-peptides-is-irreversible/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/freezing-peptides-is-irreversible/</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 GMT</pubDate>
      <description>A frozen and re-thawed peptide pen looks identical to the eye, but ice crystals damage the protein structure. The mechanism of freeze-thaw aggregation and why warming doesn't fix it.</description>
    </item>
    <item>
      <title>BPC-157 reconstitution — diluent and volume</title>
      <link>https://peptide-calc.app/blog/bpc-157-reconstitution-which-diluent-how-much/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/bpc-157-reconstitution-which-diluent-how-much/</guid>
      <pubDate>Mon, 01 Jun 2026 12:00:00 GMT</pubDate>
      <description>Reconstituting BPC-157 with the wrong diluent or volume changes shelf-life, sterility, and dosing. The complete protocol: BAC water vs saline, target concentration, draw math.</description>
    </item>
    <item>
      <title>GLP-1 nausea peaks weeks 1–4</title>
      <link>https://peptide-calc.app/blog/glp1-nausea-peaks-weeks-1-4-after-dose-bump/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/glp1-nausea-peaks-weeks-1-4-after-dose-bump/</guid>
      <pubDate>Sun, 31 May 2026 12:00:00 GMT</pubDate>
      <description>Nausea on semaglutide and tirzepatide follows a predictable curve: peaks at 48–72 hours after the first dose at a new step, declines through week 3, near-baseline by week 4.</description>
    </item>
    <item>
      <title>Compounded semaglutide concentration errors</title>
      <link>https://peptide-calc.app/blog/compounded-semaglutide-concentration-errors-er-visits/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/compounded-semaglutide-concentration-errors-er-visits/</guid>
      <pubDate>Sun, 31 May 2026 12:00:00 GMT</pubDate>
      <description>Compounded semaglutide concentrations vary across pharmacies. Patients confusing pen-dose numbers with compounded-vial volumes have hospitalized themselves. How to verify before drawing.</description>
    </item>
    <item>
      <title>Retatrutide Phase 3 — 32% weight loss</title>
      <link>https://peptide-calc.app/blog/retatrutide-phase-3-thirty-two-percent-weight-loss/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/retatrutide-phase-3-thirty-two-percent-weight-loss/</guid>
      <pubDate>Sat, 30 May 2026 12:00:00 GMT</pubDate>
      <description>Retatrutide adds glucagon to the GIP/GLP-1 stack. Phase 3 trials project ~24% body weight loss at top dose, with mid-stage data running toward 32% in some cohorts.</description>
    </item>
    <item>
      <title>Abdomen-quadrant rotation for weekly GLP-1</title>
      <link>https://peptide-calc.app/blog/abdomen-quadrant-rotation-glp1-pens/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/abdomen-quadrant-rotation-glp1-pens/</guid>
      <pubDate>Sat, 30 May 2026 12:00:00 GMT</pubDate>
      <description>A concrete 8-zone abdominal rotation for once-weekly semaglutide and tirzepatide. The map, the cadence, and how to never inject the same patch twice in 2 months.</description>
    </item>
    <item>
      <title>Hitting 1.2–1.5 g/kg protein on GLP-1</title>
      <link>https://peptide-calc.app/blog/protein-target-glp1-1-2-1-5-grams-per-kg/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/protein-target-glp1-1-2-1-5-grams-per-kg/</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 GMT</pubDate>
      <description>On semaglutide or tirzepatide, the muscle-preservation protein target is 1.2–1.5 g/kg body weight per day. The per-meal math and why most users miss it.</description>
    </item>
    <item>
      <title>U-100 syringes show volume, not mass</title>
      <link>https://peptide-calc.app/blog/u100-syringes-show-volume-not-mass/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/u100-syringes-show-volume-not-mass/</guid>
      <pubDate>Fri, 29 May 2026 12:00:00 GMT</pubDate>
      <description>The &quot;units&quot; on a U-100 insulin syringe are a volume scale, not a peptide mass. 10 units = 0.1 mL. How to convert your dose into the right number of units.</description>
    </item>
    <item>
      <title>Semaglutide 56-day vs tirzepatide 21-day room-temp</title>
      <link>https://peptide-calc.app/blog/semaglutide-56-day-tirzepatide-21-day-room-temp/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/semaglutide-56-day-tirzepatide-21-day-room-temp/</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 GMT</pubDate>
      <description>A semaglutide pen tolerates 56 days outside the fridge. A tirzepatide pen only 21 days. Why the labels differ and what to do at week 4 of a tirzepatide pen.</description>
    </item>
    <item>
      <title>Oral semaglutide and the 30-minute empty-stomach rule</title>
      <link>https://peptide-calc.app/blog/oral-semaglutide-empty-stomach-30-minute-rule/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/oral-semaglutide-empty-stomach-30-minute-rule/</guid>
      <pubDate>Thu, 28 May 2026 12:00:00 GMT</pubDate>
      <description>Oral semaglutide (Rybelsus) bioavailability collapses if you eat or drink within 30 minutes. The strict morning protocol and why the SNAC enhancer demands it.</description>
    </item>
    <item>
      <title>Eat protein first when GLP-1 shrinks your meals</title>
      <link>https://peptide-calc.app/blog/eat-protein-first-glp1-shrinking-meals/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/eat-protein-first-glp1-shrinking-meals/</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 GMT</pubDate>
      <description>When fullness hits after 4–6 bites on a GLP-1, those bites have to deliver the protein. Practical strategy and protein-density numbers for shrinking meals.</description>
    </item>
    <item>
      <title>FDA warnings on compounded BPC-157 and TB-500</title>
      <link>https://peptide-calc.app/blog/bpc-157-tb-500-fda-warnings-immunogenicity/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/bpc-157-tb-500-fda-warnings-immunogenicity/</guid>
      <pubDate>Wed, 27 May 2026 12:00:00 GMT</pubDate>
      <description>The FDA has flagged BPC-157 and TB-500 for limited human safety data, immunogenicity risk, and impurity profiles. What the warnings actually say and what they don't.</description>
    </item>
    <item>
      <title>Tirzepatide vs semaglutide: the GIP receptor edge</title>
      <link>https://peptide-calc.app/blog/tirzepatide-vs-semaglutide-gip-receptor/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/tirzepatide-vs-semaglutide-gip-receptor/</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 GMT</pubDate>
      <description>Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is GLP-1 only. The GIP arm adds insulin-sensitizing and appetite effects worth ~5 extra body-weight percentage points.</description>
    </item>
    <item>
      <title>FDA 2026 ends 503B bulk semaglutide and tirzepatide</title>
      <link>https://peptide-calc.app/blog/fda-2026-503b-bulk-list-semaglutide-tirzepatide/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/fda-2026-503b-bulk-list-semaglutide-tirzepatide/</guid>
      <pubDate>Tue, 26 May 2026 12:00:00 GMT</pubDate>
      <description>The FDA's 2026 decision to exclude semaglutide and tirzepatide from outsourcing-facility bulk lists ends most large-scale compounding. What it means for compounded supply.</description>
    </item>
    <item>
      <title>Missed-dose rules: Ozempic vs Mounjaro vs Wegovy</title>
      <link>https://peptide-calc.app/blog/missed-dose-rules-ozempic-mounjaro-wegovy/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/missed-dose-rules-ozempic-mounjaro-wegovy/</guid>
      <pubDate>Mon, 25 May 2026 12:00:00 GMT</pubDate>
      <description>The labeled rescue windows differ by drug. Ozempic 5 days, Mounjaro 4 days, Wegovy 2 days. What to do when you miss each, and when to wait for the next scheduled dose.</description>
    </item>
    <item>
      <title>Lipohypertrophy and unpredictable insulin absorption</title>
      <link>https://peptide-calc.app/blog/lipohypertrophy-insulin-absorption-unpredictable/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/lipohypertrophy-insulin-absorption-unpredictable/</guid>
      <pubDate>Mon, 25 May 2026 12:00:00 GMT</pubDate>
      <description>Lipohypertrophy — thickened lumpy tissue under the skin from repeated injections at the same site — causes 20–30% variability in insulin absorption and matters for any subcutaneous peptide.</description>
    </item>
    <item>
      <title>Why a slower semaglutide titration reduces nausea</title>
      <link>https://peptide-calc.app/blog/slower-semaglutide-titration-reduces-nausea/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/slower-semaglutide-titration-reduces-nausea/</guid>
      <pubDate>Sun, 24 May 2026 12:00:00 GMT</pubDate>
      <description>The 0.25 → 2.4 mg semaglutide ladder is conservative for a reason. Slower bumps let the gut adapt and cut peak-week nausea by roughly half in practice.</description>
    </item>
    <item>
      <title>mg vs mL: the 1,000× peptide dosing error</title>
      <link>https://peptide-calc.app/blog/mg-vs-ml-1000x-peptide-dosing-error/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/mg-vs-ml-1000x-peptide-dosing-error/</guid>
      <pubDate>Sun, 24 May 2026 12:00:00 GMT</pubDate>
      <description>Confusing milligrams (mass) with milliliters (volume) is the most common 1,000× peptide overdose error. The unit literacy you need before drawing.</description>
    </item>
    <item>
      <title>Does reconstituted Tirzepatide need to stay cold in transit?</title>
      <link>https://peptide-calc.app/blog/tirzepatide-cold-chain-in-transit/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/tirzepatide-cold-chain-in-transit/</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
      <description>The 2–8 °C rule vs real-world transit conditions. What degrades, how fast, and the FRIO / insulated-pouch thresholds that actually matter.</description>
    </item>
    <item>
      <title>Why your BPC-157 turned cloudy (and what it means)</title>
      <link>https://peptide-calc.app/blog/why-bpc-157-turned-cloudy/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/why-bpc-157-turned-cloudy/</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
      <description>Five causes of cloudy reconstituted BPC-157 — from temperature shock to bacterial contamination — and which are still usable.</description>
    </item>
    <item>
      <title>Can you mix BPC-157 and TB-500 in the same syringe?</title>
      <link>https://peptide-calc.app/blog/mixing-bpc-157-and-tb-500-same-syringe/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/mixing-bpc-157-and-tb-500-same-syringe/</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
      <description>The compatibility question for the most common healing stack. Why mixing is usually fine, the two cases it isn't, and the math to do it safely.</description>
    </item>
    <item>
      <title>How to split a subq peptide dose across two sites</title>
      <link>https://peptide-calc.app/blog/splitting-subq-peptide-dose-two-sites/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/splitting-subq-peptide-dose-two-sites/</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
      <description>When splitting makes sense (large volumes, injection-site reactions, lipohypertrophy avoidance) and the technique that keeps kinetics intact.</description>
    </item>
    <item>
      <title>What happens if you skip a Semaglutide dose</title>
      <link>https://peptide-calc.app/blog/skipping-semaglutide-dose-titration-restart/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/skipping-semaglutide-dose-titration-restart/</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
      <description>The 5-day rule, when to resume at the same dose, when to titrate back down, and why restarting the escalation accidentally is the common mistake.</description>
    </item>
    <item>
      <title>Reading a COA: what 98% purity actually means</title>
      <link>https://peptide-calc.app/blog/what-98-percent-purity-on-a-coa-actually-means/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/what-98-percent-purity-on-a-coa-actually-means/</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
      <description>The math behind a HPLC purity number, what the remaining 2% usually is, and why 98% on one vendor's COA is not the same as 98% on another's.</description>
    </item>
    <item>
      <title>Why peptide pricing varies 5× between vendors</title>
      <link>https://peptide-calc.app/blog/why-peptide-pricing-varies-five-times/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/why-peptide-pricing-varies-five-times/</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
      <description>Same compound, same purity claim, a fivefold spread. What is actually driving the price — and which pricing tiers are worth paying for.</description>
    </item>
    <item>
      <title>Peptide travel: 2026 country-by-country customs rundown</title>
      <link>https://peptide-calc.app/blog/peptide-travel-country-customs-rundown-2026/</link>
      <guid isPermaLink="true">https://peptide-calc.app/blog/peptide-travel-country-customs-rundown-2026/</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
      <description>Tactical 2026 snapshot: US, UK, EU, Canada, Australia, Japan, UAE, Singapore. Enforcement posture, airline rules, and a pre-trip checklist.</description>
    </item>
  </channel>
</rss>
